

Special Issue

Innovations in Cancer Immunology: Personalized Therapeutic Approaches

Message from the Guest Editor

The field of cancer immunology has transformed cancer treatment, offering personalized therapies tailored to the unique tumor microenvironment (TME) of each patient. The TME—including immune cells, stromal elements, the extracellular matrix, and the microbiome—plays a pivotal role in determining immunotherapy outcomes. Tumors often reshape their microenvironment to evade immune detection, posing major challenges for effective and personalized interventions. This Special Issue aims to present recent advances in immunotherapy, including the identification of novel targets, patient stratification methods, treatment monitoring tools, and strategies to overcome resistance. We welcome submissions exploring innovative technologies such as single-cell sequencing, artificial intelligence, and nanomedicine. Studies on combining immunotherapy with targeted therapy, radiation, or gene editing are also encouraged. We invite original research, reviews, and other contributions that promote safer, more effective personalized cancer immunotherapies.

Guest Editor

Dr. Samantha Sharma

Medical and Molecular Genetics, Indiana University School of Medicine,
R3 Building 980 W. Walnut Street, Room C260 Indianapolis, IN 46202,
USA

Deadline for manuscript submissions

closed (25 May 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/215658

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).